Latest news
Loading news…
Chemomab
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 HighHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals. Tel Aviv, Israel Founded 2011 11-50 employees For Profit
Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics.
Chemomab on Acquirezy — acquisitions, funding rounds, investments, investors, key people & contacts.
Chemomab was acquired by Scipher Medicine in 2026 for $150M.
Total Funding
$90.5M
Funding Rounds
5
Last Funding
Acquisitions
2
Monthly Visits
Contacts
13
Ticker
CMMB
NASDAQ
Patents
0
3 trademarks
About Chemomab
Funding & Financials
- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Public
- Ticker
- CMMB
- Exchange
- NASDAQ
- IPO date
- Mar 16, 2021
Web Traffic
- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 48
- Patents granted
- 0
- Trademarks
- 3
Company Info
- Founded
- 2011
- Employees
- 11-50
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- Founders
- 1
- News articles
- 87
- HQ
- Tel Aviv, Israel
- Region
- Europe, Middle East, and Africa (EMEA), Middle East, Middle East and North Africa (MENA)
- Exit date
- Mar 16, 2021
Signals & Scores
- Heat score
- High
- Growth score
- Low
- Trend (7d)
- 4.7
- Trend (30d)
- 8.6
- Trend (90d)
- 8.4
- Last leadership hire
- Oct 1, 2026
Chemomab Funding Rounds
5 results
Upgrade to Pro to view this datasetUpgrade
| Organization Name | Funding Type | Lead Investor Names | Org Hq Country | ||
|---|---|---|---|---|---|
1–5 of 5Show
Page 1 / 1
Chemomab Acquisitions
2 results
| Acquiree Name | Acquirer Name | Acquiree Industries | Acquiree Hq Country | ||
|---|---|---|---|---|---|
| Scipher Medicine | $15M | 2026-07-08 | Chemomab | Alternative MedicineBiotechnologyGeneticsHealth CareHealth Diagnostics | United States |
| Anchiano Therapeutics | — | 2021-03-16 | Chemomab | BiotechnologyHealth CareMedical Device | Israel |
1–2 of 2Show
Page 1 / 1
Chemomab Key People
Chief Financial Officer, Executive Vice President and COO
Vice President, R&D
Co-Founder, Chief Executive Officer and Chief Scientific Officer
Chief Medical Officer
Vice President, Global Clinical Development Operations
13
professional contacts at Chemomab
Contact execs at Chemomab →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Bulk Dataset Export
Need the data in bulk? Buy the entire dataset.
5.4M company profiles200K+ acquisitions700K+ funding rounds327K investors2M+ people61M contacts45K schools
Delivered as CSV, JSON or Parquet — at startup-friendly pricing.
FAQs about Chemomab
People who checked this page also checked these
Sectors Chemomab invests & acquires in
Browse the full Acquirezy directory.